Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Chie Yanagisawa is active.

Publication


Featured researches published by Chie Yanagisawa.


Applied and Environmental Microbiology | 2010

Occurrence and Molecular Characteristics of Methicillin-Resistant Staphylococcus aureus and Methicillin-Resistant Staphylococcus pseudintermedius in an Academic Veterinary Hospital

Kanako Ishihara; Natsumi Shimokubo; Akie Sakagami; Hiroshi Ueno; Yasukazu Muramatsu; Tsuyoshi Kadosawa; Chie Yanagisawa; Hideaki Hanaki; Chie Nakajima; Yasuhiko Suzuki; Yutaka Tamura

ABSTRACT Recently, methicillin-resistant Staphylococcus aureus (MRSA) and methicillin-resistant Staphylococcus pseudintermedius (MRSP) have been increasingly isolated from veterinarians and companion animals. With a view to preventing the spread of MRSA and MRSP, we evaluated the occurrence and molecular characteristics of each in a veterinary college. MRSA and MRSP were isolated from nasal samples from veterinarians, staff members, and veterinary students affiliated with a veterinary hospital. Using stepwise logistic regression, we identified two factors associated with MRSA carriage: (i) contact with an identified animal MRSA case (odds ratio [OR], 6.9; 95% confidence interval [95% CI], 2.2 to 21.6) and (ii) being an employee (OR, 6.2; 95% CI, 2.0 to 19.4). The majority of MRSA isolates obtained from individuals affiliated with the veterinary hospital and dog patients harbored spa type t002 and a type II staphylococcal cassette chromosome mec (SCCmec), similar to the hospital-acquired MRSA isolates in Japan. MRSA isolates harboring spa type t008 and a type IV SCCmec were obtained from one veterinarian on three different sampling occasions and also from dog patients. MRSA carriers can also be a source of MRSA infection in animals. The majority of MRSP isolates (85.2%) carried hybrid SCCmec type II-III, and almost all the remaining MRSP isolates (11.1%) carried SCCmec type V. MRSA and MRSP were also isolated from environmental samples collected from the veterinary hospital (5.1% and 6.4%, respectively). The application of certain disinfection procedures is important for the prevention of nosocomial infection, and MRSA and MRSP infection control strategies should be adopted in veterinary medical practice.


Journal of Infection and Chemotherapy | 2009

Linezolid-resistant methicillin-resistant Staphylococcus aureus isolated after long-term, repeated use of linezolid

Koichiro Yoshida; Hisashi Shoji; Hideaki Hanaki; Chie Yanagisawa; Yurika Ikeda-Dantsuji; Kunihiko Fukuchi; Mitsuru Adachi; Yoshihito Niki

We report a 54-year-old male patient with an infection caused by linezolid-resistant methicillin-resistant Staphylococcus aureus (MRSA), isolated after long-term, repeated use of linezolid. Five MRSA strains isolated from our patient were preserved and submitted to bacteriological analysis. All five of these strains were found to have identical genotypes by pulsed-field gel electrophoresis. Two strains isolated in the early hospital period were sensitive to linezolid, while three isolated in the late hospital period were resistant. These three strains that had acquired resistance to linezolid were found to have a G2576T point mutation in the 23SrRNA domain V. Linezolid-resistant MRSA is rare, but may occur with the long-term, repeated administration of linezolid.


Antimicrobial Agents and Chemotherapy | 2009

Rapid Depletion of Free Vancomycin in Medium in the Presence of β-Lactam Antibiotics and Growth Restoration in Staphylococcus aureus Strains with β-Lactam-Induced Vancomycin Resistance

Chie Yanagisawa; Hideaki Hanaki; Hidehito Matsui; Shinsuke Ikeda; Taiji Nakae; Keisuke Sunakawa

ABSTRACT A class of methicillin-resistant Staphylococcus aureus strains shows vancomycin resistance in the presence of β-lactam antibiotics (β-lactam-induced VAN-resistant methicillin-resistant S. aureus [BIVR]). Two possible explanations may be offered: (i) vancomycin in culture medium is depleted, and (ii) the d-Ala-d-Ala terminal of the peptidoglycan network is replaced with d-Ala-d-lactate. We tested these hypotheses by quantifying free vancomycin in the medium through the course of cell growth and by PCR amplification of the van genes. Growth of the BIVR cells to an absorption level of ∼0.3 at 578 nm required about 24 h in the presence of vancomycin alone at the MIC (4.0 μg/ml). However, growth was achieved in only about 10 h when 1/1,000 to 1/2,000 the MIC of β-lactam antibiotic was added 2 h prior to the addition of vancomycin, suggesting that the β-lactams shortened the time to recovery from vancomycin-mediated growth inhibition. Free vancomycin in the culture medium decreased to 2.3 μg/ml in the first 8 h in the culture containing vancomycin alone, yet cell growth was undetectable. When the vancomycin concentration dropped below ∼1.5 μg/ml at 24 h, the cells began to grow. In the culture supplemented with the β-lactam 2 h prior to the addition of vancomycin, the drug concentration continuously dropped from 4 to 0.5 μg/ml in the first 8 h, and the cells began to grow at a vancomycin concentration of ∼1.7 μg/ml or at 4 h of incubation. The gene encoding the enzyme involved in d-Ala-d-lactate synthesis was undetectable. Based on these results, we concluded that BIVR is attributable mainly to a rapid depletion of vancomycin in the medium triggered or promoted by β-lactam antibiotics.


The Journal of Antibiotics | 2010

Identification of the active component that induces vancomycin resistance in MRSA

Shinsuke Ikeda; Hideaki Hanaki; Chie Yanagisawa; Yurika Ikeda-Dantsuji; Hidehito Matsui; Masato Iwatsuki; Kazuro Shiomi; Taiji Nakae; Keisuke Sunakawa; Satoshi Omura

A fraction of methicillin-resistant Staphylococcus aureus (MRSA) shows resistance to vancomycin (VCM) in the presence of β-lactam antibiotics (BIVR) at low concentrations. We hypothesized that the BIVR phenomenon might be exerted by a peptidoglycan derivative(s) generated as a consequence of β-lactam antibiotic action. To verify this hypothesis, we isolated the fraction that mimicked the effect of β-lactam antibiotics by the enzymatic treatment of the crude cell wall. The active components were purified by a combination of reverse phase chromatographies, mass spectrum and amino-acid analyses, and were identified to be a muropeptide with the following formula: N-acetyglucosamyl-N-acetylmuramyl--Ala-D-isoGln-L-Lys-(ɛ-NH-4Gly)-D-Ala-2Gly. This is the very first identification of the active component, which induces VCM resistance in MRSA. We found that the BIVR cells are highly sensitive to this compound rendering the cells resistant to VCM compared with non-BIVR MRSA.


Journal of Infection and Chemotherapy | 2009

Characterization of β-lactam antibiotic-induced vancomycin-resistant MRSA (BIVR) in a patient with septicemia during long-term vancomycin administration

Yoshio Yamaguchi; Hideaki Hanaki; Chie Yanagisawa; Yurika Ikeda-Dantsuji; Takeo Hashimoto; Harunori Yazaki; Keiko Sugahara; Takashi Yanagisawa; Hiroki Kawajiri; Shizue Sato; Aki Ishizaki; Rika Tachihara-Sato; Yasuhisa Takahashi; Taro Ono; Yo Kageyama; Tomohumi Kawaguchi; Akihiko Tamura; Kazuhiko Hagane; Keisuke Sunakawa

It was reported that some methicillin-resistant Staphylococcus aureus (MRSA) show resistance to vancomycin (VCM) and β-lactam antibiotics; thus, they are termed β-lactam antibiotic-induced VCM-resistant MRSA (BIVR). The VCM resistance of MRSA is induced by the administration of β-lactam antibiotics, but this phenomenon can be difficult to detect in the clinical laboratory. We detected the BIVR strain in a 64-year-old man who had had a ventilator tube inserted directly into the windpipe during long-term VCM therapy. The patient was diagnosed with MRSA pneumonia and septicemia on July 5, 2007, and sulbactam/ampicillin (SBT/ABPC) was administered for 5 days. However, the fever recurred, and administration of VCM was resumed for 7 days from July 19. Fever developed again, and VCM was administered again for 14 days from September 30. BIVR and VCM-low-sensitive MRSA were isolated from blood on October 18 and 22, although the VCM trough concentration was 10.2 µg/ml. On October 27, we changed to a combination of fosfomycin (FOM) and arbekacin (ABK), and thereafter the fever quickly decreased and the clinical symptoms abated. We isolated five MRSA strains from the blood of the patient, three strains of VCM-sensitive MRSA, one strain of BIVR, and one strain of a VCM-low-sensitive MRSA. The DNA band patterns determined by pulsed-field gel electrophoresis were completely identical except for the VCM-low-sensitive MRSA, which was missing one band. Furthermore, the VCM-low-sensitive MRSA became sensitive to β-lactam antibiotics. Our results indicate the possibility that long-term VCM therapy is one of the factors that allow BIVR or VCM-low-sensitive MRSA to emerge, and this allows VCM therapy for MRSA to fail.


Journal of Infection and Chemotherapy | 2005

JIC Award 2006

Yasuko Hososaka; Hideaki Hanaki; Chie Yanagisawa; Yukie Yamaguchi; Hidehito Matsui; Taiji Nakae; S. Iwata; Izumi Hayashi; Keisuke Sunakawa

Abstract We report here an outbreak of β-lactam-induced vancomycin-resistant methicillin- resistant Staphylococcus aureus (MRSA; BIVR) at one of the Cancer-Institute-affiliated hospitals in Tokyo. We examined a total of 500 strains (100 per year) of clinically isolated MRSA from 1998 to 2002. The detection rates of BIVR in the years 1998, 1999, 2000, 2001, and 2002 were 10%, 9%, 49%, 15%, and 19%, respectively. To investigate the cause of the high incidence of BIVR detection in the year 2000, we carried out pulsed-field gel electrophoresis (PFGE) of the SmaI -digested chromosomal DNA of BIVR and MRSA. The results showed that 96% of the BIVR strains isolated in 2000 were classified as an identical DNA type “A”, while only 47% of the MRSA strains were classified as this type. We concluded, based on these results, that this hospital had a nosocomial infection of BIVR in the year 2000. An important message given by this study would be that nosocomial BIVR infection could occur in any hospital where MRSA infection is treated with vancomycin and β-lactam antibiotics.


Journal of Infection and Chemotherapy | 2007

Neutralization of staphylococcal exotoxins in vitro by human-origin intravenous immunoglobulin

Chie Yanagisawa; Hideaki Hanaki; Taiji Natae; Keisuke Sunakawa


Journal of Infection and Chemotherapy | 2011

Linezolid-resistant Staphylococcus aureus isolated from 2006 through 2008 at six hospitals in Japan

Yurika Ikeda-Dantsuji; Hideaki Hanaki; Fuminori Sakai; Kazunori Tomono; Yoshio Takesue; Junichi Honda; Yuriko Nonomiya; Akira Suwabe; Osanori Nagura; Katsunori Yanagihara; Hiroshige Mikamo; Kunihiko Fukuchi; Mitsuo Kaku; Shigeru Kohno; Chie Yanagisawa; Taiji Nakae; Koichiro Yoshida; Yoshihito Niki


Journal of Infection and Chemotherapy | 2007

Occurrence of vancomycin-intermediate-resistant Staphylococcus aureus in Japan

Hideaki Hanaki; Yasuko Hososaka; Chie Yanagisawa; Yoshihito Otsuka; Zenzo Nagasawa; Taiji Nakae; Keisuke Sunakawa


Journal of Infection and Chemotherapy | 2005

Investigation of β-lactam antibiotic-induced vancomycin-resistant MRSA (BIVR)

Hideaki Hanaki; Yoshio Yamaguchi; Chie Yanagisawa; Kazuaki Uehara; Hidehito Matsui; Yukie Yamaguchi; Yasuko Hososaka; Kazunari Barada; Fumiko Sakai; Yasuko Itabashi; Shinsuke Ikeda; Koichiro Atsuda; Haruo Tanaka; Takashi Inamatsu; Ariaki Nagayama; Keisuke Sunakawa

Collaboration


Dive into the Chie Yanagisawa's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge